Stem Cells News and Research

RSS

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

Scientists identify biochemical abnormality behind Machado-Joseph disease

Scientists in Portugal have identified a biochemical abnormality behind the potentially fatal neurodegenerative Machado-Joseph disease and using several models of the disease were able to reverse the problem in what can be a crucial step towards a cure for humans .

2 May 2011

ARVO announces 2011 award recipients in retinal research

The Association for Research in Vision and Ophthalmology is pleased to announce its 2011 ARVO Award recipients. These award recipients will be acknowledged at the ARVO 2011 Annual Meeting, May 1 - 5, in Fort Lauderdale, Fla.

2 May 2011

Appeals court restores federal funding of stem cell research

Government financing of human embryonic stem cell research can continue, a federal appeals court ruled Friday. The decision was an important victory for the Obama administration in a legal battle that is far from over.

2 May 2011

Stanford University creates first stem cell science PhD program in U.S.

Stanford University’s Faculty Senate has approved the creation of what officials believe is the first stem cell science PhD program in the nation and, perhaps, the world. The new doctoral program in stem cell biology and regenerative medicine is also the first interdisciplinary doctoral program created by the School of Medicine in recent years.

1 May 2011

US Appeals Court overturns ban on federal funding of embryonic stem cell research

The U.S. Federal Court of Appeals has overturned an August 2010 ban on federal funding of embryonic stem cell research, paving the way for broader exploration of how stem cells function and how they can be harnessed to treat a wide range of currently incurable diseases.

30 Apr 2011

FRC expresses disappointment over federal taxpayer funding of embryonic stem cell research

Family Research Council expressed disappointment in a 2-1 split decision today by the U.S. Court of Appeals in Washington, D.C. that allows the Obama administration to continue federal taxpayer funding of embryonic stem cell research.

30 Apr 2011

UCLA study findings hold promise to cure diabetes

Simply put, people develop diabetes because they don't have enough pancreatic beta cells to produce the insulin necessary to regulate their blood sugar levels.

30 Apr 2011

Invivo Therapeutics' Chief Science Officer selected as recipient of 2011 Apple Award

InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, today announced that Chief Science Officer Dr. Christopher Pritchard, Ph.D., has been selected as the 2011 recipient of the American Spinal Injury Association's prestigious Apple Award.

30 Apr 2011

University of South Florida researcher earns Everfront Award for stem cell study

Dr. Paul Sanberg, Distinguished University Professor and senior associate vice president for research and innovation at the University of South Florida, received the Everfront Award at the 4th Pan Pacific Symposium on Stem Cell and Cancer Research held earlier this month in Taichung, Taiwan.

30 Apr 2011

Researchers develop new gene therapy technique for CGD treatment

Researchers have developed an effective technique that uses gene therapy on stem cells to correct chronic granulomatous disease in cell culture, which could eventually serve as a treatment for this rare, inherited immune disorder, according to a study published in Blood, the Journal of the American Society of Hematology.

29 Apr 2011

MorphoSys reaches second clinical milestone with OncoMed Pharmaceuticals

MorphoSys AG announced today that it has received a milestone payment from OncoMed Pharmaceuticals in connection with the FDA acceptance of an IND for a HuCAL-derived, fully human antibody. The antibody OMP-18R5, which targets the Wnt signaling pathway, will be evaluated in a Phase 1 trial in the US in patients with advanced solid tumors.

29 Apr 2011

Experts to present stem cell therapies for neurological disorders at Cedars-Sinai conference

Experts from stem cell programs at respected research centers around the country will present information at an April 30 conference on stem cell therapy for neurological disorders, hosted by the Department of Neurosurgery at Cedars-Sinai Medical Center in collaboration with the Genetics Policy Institute of Wellington, Fla.

29 Apr 2011

AquaStar granted U.S. Patent for Portable Capillary Sensor technology used in Capwave ELISA platform

AquaStar Holdings, Inc. is pleased to announce that the United States Patent and Trademark Office has issued patent number 7,708,944 for the Ultra-Sensitive, Portable Capillary Sensor technology utilized by the Capwave Enzyme-Linked Immuno-Sorbent Assay (ELISA) platform.

28 Apr 2011

FDA accepts OncoMed's IND filing for OMP-18R5 in Phase 1 clinical trial for advanced solid tumors

OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells or tumor-initiating cells, today announced that the FDA has accepted an IND filing for OMP-18R5, which allows OncoMed to commence Phase 1 clinical testing.

28 Apr 2011

New discovery in cancer and autoimmune diseases

Researchers in the Faculty of Medicine & Dentistry at the University of Alberta have made an important discovery that provides a new understanding of how our immune system "learns" not to attack our own body, and this could affect the way doctors treat patients with autoimmune diseases and cancer.

28 Apr 2011

ISCO completes first series of hepatocytes preclinical testing

International Stem Cell Corporation announces successful completion of the first series of preclinical testing of hepatocytes derived in the lab from human parthenogenetic stem cells.

27 Apr 2011

Tarix begins patient enrollment for TXA127 Phase 1 study in DCBT

Tarix Pharmaceuticals today announced enrollment of the first patient in a Phase 1 clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.

27 Apr 2011

Experts to present research on vascular biology and disease at ATVB meetings

Nearly 1,200 experts in cardiovascular medicine, vascular biology, endocrinology, hematology and other disciplines are expected to attend the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions, April 28-30, in Chicago, Ill.

26 Apr 2011

Researchers report game-changing advance in stem cell science

In a paper published in the April 25 early online edition of the Proceedings of the National Academy of Sciences, researchers at the University of California, San Diego School of Medicine, the Gladstone Institutes in San Francisco and colleagues report a game-changing advance in stem cell science: the creation of long-term, self-renewing, primitive neural precursor cells from human embryonic stem cells that can be directed to become many types of neuron without increased risk of tumor formation.

26 Apr 2011

New discoveries in stem-cell technology

A scientist at the Gladstone Institutes has made two significant stem-cell discoveries that advance medicine and human health by creating powerful new approaches for using stem cells and stem-cell-like technology.

26 Apr 2011